KALA BIO (NASDAQ:KALA) Earns Buy Rating from HC Wainwright

KALA BIO (NASDAQ:KALA)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 118.34% from the company’s current price.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

KALA BIO Trading Up 1.6 %

KALA BIO stock traded up $0.11 during midday trading on Friday, hitting $6.87. 8,914 shares of the stock were exchanged, compared to its average volume of 83,799. The company has a current ratio of 2.15, a quick ratio of 3.07 and a debt-to-equity ratio of 3.18. The stock’s 50-day simple moving average is $6.00 and its 200 day simple moving average is $6.29. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $10.97. The stock has a market capitalization of $31.67 million, a price-to-earnings ratio of -0.55 and a beta of -2.13.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. On average, equities analysts anticipate that KALA BIO will post -11.76 EPS for the current year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.